

研究成果の刊行に関する一覧表
雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Iuchi T, et al.	Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomized study	J Neurol Neurosurg Psychiatry			Epub ahead of print
Takami H, Mukasa A, et al.	Findings from positron emission tomography and genetic analyses for cerebellar liponeurocytoma.	Brain Tumor Pathol.			Epub ahead of print
Miyatake-S, et al.	Pathophysiology, Diagnosis and Treatment of Radiation Necrosis in the Brain.	Neurologia medico-chirurgica	55	50-59	2015
Mizumoto M, Miyatake S, Tsuboi K, et al	Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy.	Pract Radiat Oncol.	5(1)	e9-e16	2015
Arita H, Narita Y, et al.	Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.	Brain Tumor Pathol.	32(1)	22-30	2015
Yoritsune E, Miyatake S, et al.	Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis.	J Radiat Res.	55(4)	803-811	2014
Futamura G, Miyatake-SI, et al.	A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy.	Radiat Oncol.	9(1)	237	2014
Miyatake S-I, et al.	Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases	Radiation Oncology	9	6-	2014
Hirota Y, Miyatake S-I, et al	High linear-energy-transfer radiation can overcome radioresistance of glioma stem-like cells to low linear-energy-transfer radiation	Journal of Radiation Research	55	75-83	2014
Miyata T, Miyatake S-I, et al	The roles of platelet-derived growth factors and their receptors in brain radiation necrosis	Radiation Oncology	9	51-	2014

Iuchi T, et al.	Phase 2 Trial of Hypofractionated High-Dose Intensity Modulated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma	Int J Radiat Oncol Biol Phys	88(4)	793-800	2014
Yamaguchi S, Terasaka S, et al.	Prognostic Factors for Survival in Patients with High-Grade Meningioma and Recurrence-Risk Stratification for Application of Radiotherapy	PLoS One	12; 9(5):	e97108	2014
Yamaguchi S, Terasaka S, et al.	Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.	Acta Neurochir	157(2)	187-194	2014
Momose T, Nariai T, et al.	Clinical benefit of 11C methionine PET imaging as a planning modality for radiosurgery of previously irradiated recurrent brain metastases.	Clin Nucl Med	39	939-943	2014
Yamamoto M, Nariai T, et al.	Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors.	J Neurosurg	121	16-25	2014
Saura H, Beppu T, et al.	Intractable yawning associated with mature teratoma of the supramedial cerebellum	J Neurosurg	121	387-389	2014
Watanabe T, Arakawa Y, et al.	Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases	Molecular and Clinical Oncology	2	197-202	2014
Kakigi T, Arakawa Y, et al.	Quantitative imaging values of CT, MR, and FDG-PET to differentiate pineal parenchymal tumors and germinomas: are they useful?	Neuroradiology	56	297-303	2014
Yamamoto T, Nakamura H, et al.	Characteristics of brain metastases from esophageal carcinoma.	Surg Neurol Int	5	137	2014
Arita H, Narita Y, et al.	Risk factors for early death after surgery in patients with brain metastases: reevaluation of the indications for and role of surgery.	J Neurooncol	116(1)	145-52	2014
Feng H, Nagane M, et al.	EGFR Phosphorylation of DCBLD2 Recruits TRAF6 and Stimulates Akt-promoted Tumorigenesis.	J Clin Invest.	124(9)	3741-3756	2014

Nagane M, et al.	Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.	Int J Clin Oncol	19	16-23	2014
Miwa K, Shinoda J, et al.	Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy.	Radiat Oncol.	9	181	2014
Yonezawa S, Shinoda J, et al.	Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis.	J Neurooncol	119	101-109	2014
Takenaka S, Miwa K, et al.	Comparison of 11C-Methionine, 11C-Choline, and 18F-Fluorodeoxyglucose-PET for Distinguishing Glioma Recurrence from Radiation Necrosis	Neurologia medico-chirurgica	54(4)	280-289	2014
Saito T, Sugiyama K, et al.	Intraoperative cortico-cortical evoked potentials for the evaluation of language function during brain tumor resection: initial experience with 13 cases.	J Neurosurg.	121	827-838	2014
Aoki T, Sugiyama K, et al.	A multicenter phase I/II study of the BCNU implant (Gliadel® Wafer) for Japanese patients with malignant gliomas.	Neurol Med Chir (Tokyo).	54	290-301	2014
Fudaba H, Abe T	Comparison of multiple parameters obtained on 3 Tesla pulsed arterial spin-labeling, diffusion-tensor imaging and magnetic resonance spectroscopy and the Ki-67 labeling index in evaluating glioma grading.	J of Neuroradiology	35	2091-2098	2014
Aihara K, Mukasa A, et al.	H3F3A K27M mutations in thalamic gliomas from young adult patients	Neuro-Oncology	16(1)	140-146	2014
Saito K, Mukasa A, et al.	Toxicity and Outcome of Radiotherapy with Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma: A Retrospective Study	Neurologia medico-chirurgica	54(4)	272-279	2014
Sato I, Terasaki M, et al.	Cancer-specific health-related quality of life in children with brain tumors.	Quality of Life Research.	23(4)	1059-1068	2014
Sonoda Y, Kumabe T, et al.	The association of subventricular zone involvement at recurrence with survival after repeat surgery in patients with recurrent glioblastoma.	Neurol Med Chir (Tokyo)	54(4)	302-309	2014

Shih DJ, Kumabe T, et al.	Cytogenetic prognostication within medulloblastoma subgroups.	J Clin Oncol.	32(9)	886-896	2014
Kanamori M, Kumabe T, et al.	Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.	J Neurosurg	120(6)	1288-1297	2014
Miyatake S-I, et al.	Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.	Neuro Oncol.	15(6)	650-655	2013
Furuse M, Miyatake S-I, et al	Bevacizumab Treatment for Symptomatic Radiation Necrosis Diagnosed by Amino Acid PET	Jpn J Clin Oncol	43(3)	337-341	2013
Kawabata S, Miyatake S-I, et al	Boron neutron capture therapy for recurrent high-grade meningiomas.	J Neurosurg	119	837-844	2013
宮武伸一	腫瘍細胞選択的粒子線治療「ホウ素中性子捕捉療法」と抗血管新生薬による症候性脳放射線壊死の治療	脳神経外科ジャーナル	22	605-612	2013
Motegi H, Terashima S et al	IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy	Brain Tumor Pathol	30	67-72	2013
Iuchi T, et al.	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma	Lung Cancer	82	282-287	2013
Yamamoto M, Nariai T, et al.	A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: comparing treatment results for 1-4 vs ≥ 5 tumors.	J Neurosurg	118	1258-1268	2013
Sakata M, Nariai T, et al.	Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies.	Ann Nucl Med	27	285-296	2013
Yamamoto M, Nariai T, et al.	Delayed Complications in Patients Surviving at Least 3 Years After Stereotactic Radiosurgery for Brain Metastases.	Int J Radiat Oncol Biol Phys,	85	53-60	2013

Ikeda H, Tsuyuguchi N, et al.	Analysis of progression and recurrence of meningioma using 11C-D-methionine PET	Ann Nucl Med	27	772-780	2013
Beppu T, et al.	Standardized Uptake Value in High Uptake Area on Positron Emission Tomography with 18F-FRP170 as a Hypoxic Cell Tracer Correlates with Intratumoral Oxygen Pressure in Glioblastoma	Mol Imaging Biol	16	127-135	2013
Arakawa Y, et al.	Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma	Neurol Med Clin (Tokyo)	53	779-785	2013
Yoshitaka Narita, et al.	Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors	Jpn J Clin Oncol	43	587-595	2013
田部井 勇助 ほか	転移性脳腫瘍の集学的治療	癌と化学療法	40	1288-1294	2013
Takahashi Y, Nakamura H, et al.	Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients	World Journal of Surgical Oncology	11	284	2013
Suzuki K, Tsuboi K, et al.	Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress.	Neuro-Oncology	15	1186-1199	2013
Mizumoto M, Tsuboi K, et al.	Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy Technical considerations based on experience at a single institution	Strahlenther Onkol	189	656-663	2013
Nagane M, et al.	Bevacizumab for Glioblastoma—A Promising Drug or Not?	Cancers	5	1456-1468	2013
Shinoda J, Miwa K, et al.	Epilepsy surgery of dysembryoplastic neuroepithelial tumors using advanced multitechnologies with combined neuroimaging and electrophysiological examinations.	Epilepsy & Behavior Case Report	1	97-105	2013
古瀬元雅、宮武伸一	放射線脳壊死の病態と治療法	Clinical Neuroscience	31	1177-1178	2013

Kuroiwa T, Furu se M, et al.	A surgical loupe system for observing protoporphyrin IX fluorescence in high-grade gliomas after administering 5-aminolevulinic acid.	Photodiagnosis and Photodynamic Therapy	10	379-381	2013
Ooba H, Abe T, et al.	Repeated cyst formation in a patient with leukoencephalopathy, cerebral calcifications, and cysts: effectiveness of stereotactic aspiration with Ommaya reservoir placement Case report	J Neurosurg Pediatrics	12	155-159	2013
Terasaki M, et al.	Controversies in Clinical Trials of Cancer Vaccines for Glioblastoma	J Vaccines Vaccin	4	1	2013
Zhukova N, Kum abe T, et al.	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma	J Clin Oncol	31	2927-2935.	2013
Fauchon F, Kum abe T	Role of surgery, radiotherapy and chemotherapy in papillary tumors of the pineal region: a multicenter study	J Neurooncol	112	223-231	2013
Remke M, Kuma be T, et al.	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma	Acta Neuropathol	126	917-929	2013
宮武伸一、古瀬元 雅	高度医療（第3項先進医療）制度を用いた症候性脳放射線壊死の診断と治療	PET journal	18	11-13	2012
宮武伸一、古瀬元 雅	脳放射線壊死の成因と治療 - 高度医療（第3項先進医療）の申請	脳神経外科ジャーナル	21(6)	472-480	2012

Yamaguchi S, Terasaka S, et al.	The impact of extent of resection and histological subtype on the outcome of adult patients with high-grade gliomas.	Jpn J Clin Oncol	42(4)	270-277	2012
Kanno H, Terasaka S, et al.	Prognostic implication of histological oligodendroglial tumor component: Clinicopathological analysis of 111 cases of malignant gliomas.	PLoS One	7(7)	e41669	2012
Suzuki Y, Nariai T, et al.	Increased Adenosine A1 Receptor Levels in Hemianopia Patients After Cerebral Injury: An Application of PET Using ¹¹ C-8-Dicyclopropylmethyl-1-Methyl-3-Propylxanthine.	Clinical Nuclear Medicine	37(12)	1146-1151	2012

Uda T, Tsuyuguchi N, et al.	sLORETA-qm for interictal MEG epileptic spike analysis: Comparison of localization and quantity with equivalent dipole estimation	Clin Neurophysiol	123(11)	2116-21	2012
Beppu T, et al.	Fractional anisotropy in the centrum semiovale as a quantitative indicator of cerebral white matter damage in the subacute phase in patients with carbon monoxide poisoning: correlation with the concentration of myelin basic protein in cerebrospinal fluid.	J Neurol	259(8)	1698-1705	2012
Fujiwara S, Beppu T, et al.	Detecting damaged regions of cerebral white matter in the subacute phase after carbon monoxide poisoning using voxel-based analysis with diffusion tensor imaging.	Neuroradiology	54	681-689	2012
Hirata E, Arakawa Y, et al.	In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasion.	Journal of Cell Science	125	858-868	2012
Ogura K, Arakawa Y, et al.	Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors.	J Neuro-Oncol	109(2)	425-432	2012
Okita Y, Narita Y, et al.	IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.	Int J Oncol	41	1325-1336	2012
Okita Y, Narita Y, et al.	Pathological findings and prognostic factors in recurrent glioblastomas.	Brain Tumor Pathol	29(4)	192-200	2012

Ohno M, Narita Y, et al.	Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.	Brain Tumor Pathol	29(4)	183-191	2012
Komohara Y, Nakamura H, et al.	Importance of direct macrophage-tumor cell interaction on progression of human glioma.	Cancer Sci	103(12)	2165-2172	2012
Makino K, Nakamura H, et al.	Fatty acid synthase is a predictive marker for aggressiveness in meningiomas.	J Neurooncol	109(2)	399-404	2012
Kawahara Y, Nakamura H, et al.	Prediction of high-grade meningioma by preoperative MRI assessment.	J Neurooncol	108(1)	147-152	2012
Takano S, Tsuboi K, et al.	Immunohistochemical detection of IDH1 mutation, p53, and internerve as prognostic factors of glioma tumors.	J Neurooncol.	108(3)	361-373	2012
Nagane M, et al.	Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.	Jpn J Clin Oncol	42(10)	887-895	2012
Miwa K, Shinoda J, et al.	Clinical value of [(11)C] methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors.	Int J Radiat Oncol Biol Phys	84	1139-1144	2012
Matsuo M, Miwa K, Shonoda J, et al.	Impact of [11C] methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.	Int J Radiat Oncol Biol Phys	82	83-89	2012
Motomura K, Abe T, et al.	Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas	Cancer Science	103	1871-1879	2012
Mukasa A et al.	Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients	Cancer Science	103	587-592	2012
Terasaki M, et al.	Successful treatment of leptomeningeal gliomatosis of pilomyxoid astrocytoma after failed frontline chemotherapy.	The Neurologist	18(1)	32-35	2012
Terazaki Y, Terasaki M, et al.	Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer.	Cancer Science	103(4)	638-644	2012

Shibahara I, Kumabe T, et al.	IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.	Int J Clin Oncol	17(6)	551-561	2012
Sugiyama SI, Kumabe T, et al.	Safety and feasibility of convection-enhanced delivery of nimustine hydrochloride co-infused with free gadolinium for real-time monitoring in the primate brain.	Neurol Res	34	581-587	2012